http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Peter G. Rose (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
-
Kathryn Maurer,Chad Michener,Haider Mahdi,Peter G. Rose 대한부인종양학회 2017 Journal of Gynecologic Oncology Vol.28 No.4
Objective: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) inpatients with prior taxane HSR. Methods: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologicmalignancy were identified. Chart abstraction included pathology, prior therapy, indicationfor nab-paclitaxel, dosing, response, toxicities including any HSR, and reason fordiscontinuation of nab-paclitaxel therapy. Results: We identified 37 patients with gynecologic malignancies with a history of paclitaxelHSR who received nab-paclitaxel. Six patients (16.2%) had a prior HSR to both paclitaxel anddocetaxel while the other 31 patients had not received docetaxel. No patients experienced aHSR to nab-paclitaxel. Median number of cycles of nab-paclitaxel was 6 (range 2–20). Twelvepatients received weekly dosing at 60 to 100 mg/m2. The remainder of patients received 135mg/m2(n=13), 175 mg/m2(n=9), or 225 mg/m2(n=3). Thirty four patients (91.9%) receivedreceived nab-paclitaxel in combination with carboplatin (n=28, 75.7%), IP cisplatin (n=1,2.7%), carboplatin and bevacizumab (n=3, 8.1%), or carboplatin and gemcitabine (n=2,5.4%). Reasons for discontinuing nab-paclitaxel included completion of adjuvant therapy(n=16), progressive disease (n=18), toxicity (n=1), and death (n=1). There were no grade4 complications identified during nab-paclitaxel administration. Grade 3 complicationsincluded: neutropenia (n=9), thrombocytopenia (n=4), anemia (n=1), and neurotoxicity (n=1). Conclusion: Nab-paclitaxel is well-tolerated with no HSRs observed in this series of patientswith prior taxane HSR. Given the important role of taxane therapy in nearly all gynecologicmalignancies, administration of nab-paclitaxel should be considered prior to abandoningtaxane therapy
-
Haider Mahdi,Benjamin Nutter,Fadi Abdul-Karim,Sudha Amarnath,Peter G. Rose 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.2
Objective: To investigate the impact of pelvic radiation on survival in patients with uterine serous carcinoma (USC) who received adjuvant chemotherapy. Methods: Patients with stage I-IV USC were identified from the Surveillance, Epidemiology, and End Results program 2000 to 2009. Patients were included if treated with surgery and chemotherapy. Patients were divided into two groups: those who received chemotherapy and pelvic radiation therapy (CT_RT) and those who received chemotherapy only (CT). KaplanMeier curves and Cox regression proportional hazard models were used. Results: Of the 1,838 included patients, 1,272 (69%) were CT and 566 (31%) were CT_ RT. Adjuvant radiation was associated with significant improvement in overall survival (OS; p<0.001) and disease-specific survival (DSS; p<0.001) for entire cohort. These findings were consistent for the impact of radiation on OS (p<0.001) and DSS (p<0.001) in advanced stage (III-IV) disease but not for early stage (I–II) disease (p=0.21 for OS and p=0.82 for DSS). In multivariable analysis adjusting for age, stage, race and extent of lymphadenectomy, adjuvant radiation was a significant predictor of OS and DSS for entire cohort (p=0.003 and p=0.05) and in subset of patients with stage III (p=0.02 and p=0.07) but not for patients with stage I (p=0.59 and p=0.49), II (p=0.83 and p=0.82), and IV USC (p=0.50 and p=0.96). Other predictors were stage, positive cytology, African American race and extent of lymphadenectomy. Conclusion: In USC patients who received adjuvant chemotherapy, adjuvant radiation was associated with significantly improved outcome in stage III disease but not for other stages. Positive cytology, extent of lymphadenectomy and African race were significant predictors of outcome.
-
Haider Mahdi,Amelia Jernigan,Benjamin Nutter,Chad Michener,Peter G. Rose 대한부인종양학회 2015 Journal of Gynecologic Oncology Vol.26 No.3
Objective: To investigate the rate, predictors of lymph node metastasis (LNM) and pattern of recurrence in clinically early stage endometrial cancer (EC) with positive lymphovascular space invasion (LVSI). Methods: Women with clinically early stage EC and positive LVSI 2005 to 2012 were identified. Kaplan-Meier curves and logistic regression models were used. Results: One hundred forty-eight women were identified. Of them, 25.7% had LNM (21.7% pelvic LNM, 18.5% para-aortic LNM). Among patients with LNM who had both pelvic and para-aortic lymphadenectomy, isolated pelvic, para-aortic and both LNM were noted in 51.4%, 17.1%, and 31.4% respectively. Age and depth of myometrial invasion were significant predictors of LNM in LVSI positive EC. Node positive patients had high recurrence rate (47% vs. 11.8%, p<0.05) especially distant (60.9% vs. 7.9%, p<0.001) and para-aortic (13.2% vs. 1.8%, p=0.017) recurrences compared to node negative EC. LNM was associated with lower progression-free survival (p=0.002) but not overall survival (p=0.73). Conclusion: EC with positive LVSI is associated with high risk of LNM. LNM is associated with high recurrence rate especially distant and para-aortic recurrences. Adjuvant treatments should target prevention of recurrences in these areas.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
